Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders of Seagen, Blueprint Medicines, and Lilly. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced programs are focused on STAT (signal transducer and activator of transcription) proteins where abnormal activation is found in inflammatory diseases, such as rheumatoid arthritis, asthma, atopic dermatitis, and inflammatory bowel disease, as well as numerous cancer types. The company has a strategic partnership with Sanofi for the development and commercialization of a STAT6 inhibitor. Recludix is also advancing STAT3 inhibitors for Th17-mediated I&I diseases, as well as additional programs. Recludix was named a 2024 Fierce 15 biotech company.

Exalt Therapeutics is a private clinical stage USDA grant funded biotech company developing long-acting engineered species-specific cytokines that stimulate innate immunity to combat viral disease in companion animals and livestock. Co-inventor of patent (WO2020041636A1) for novel innate immunity biotherapeutic.

Everest Medicines Limited (HKEX: 1952.HK) is a public clinical stage biotech company focused on the discovery, development and commercialization of therapies addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a pipeline of multiple drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. The company was founded in 2017 by CBC Group, Asia's largest healthcare-dedicated private equity firm.

Ambrx (NASDAQ: AMAM) is a public clinical stage biologics company engaged in the discovery and development of engineered precision biologics using its proprietary expanded genetic code technology platform.Ambrx was acquired by J&J.

Led business development and out-licensing activities for development stage asset partnering processes, academic collaborations and new ventures. Sourced, coordinated diligence and negotiated out-licensing of two near clinic stage assets and establishment of two research collaborations.Array BioPharma (NASDAQ: ARRY) was acquired by Pfizer.

Led business development transactions in Europe and Emerging Markets (Eastern Europe, Middle East, Africa, Russia and Turkey) to further international expansion. Based at Amgen (Europe) GmbH headquarters in Switzerland.

Provided business development, strategy, diligence and financial support associated with the execution of multiple transactions, including product acquisitions, in-licensing, out-licensing, partnerships and company acquisitions including Micromet and deCODE. Collaborated with commercial and strategy teams to develop list of ‘needle mover’ acquisition targets aligned with future corporate net income and revenue growth goals.

Led financial planning and analysis related to insulin and growth hormone businesses inclusive of five brands with accountability for $2.5B in net sales and $450M in annual selling and marketing expenses. Managed quarterly forecasting processes, resource allocation and prioritization exercises and provided guidance to meet net sales, operating expense and net income targets.

Led financial valuation and business case analysis for M&A, in-licensing, out-licensing and divestiture transactions.

Solved equipment deviations through root cause analysis for Cymbalta, Cialis and Prozac brands as process engineer for two high speed packaging lines.